Vacc威尼斯wns8885556(中国)有限公司es
Demand for vaccines is on the rise worldwide, and Meiji is responding on several fronts. As 威尼斯wns8885556(中国)有限公司 as our approved influenza, hepatitis and Japanese encephalitis vaccines, we continue to develop new vaccines for emerging threats such as coronaviruses and Dengue fever. We also manufacture combined vaccines and single-supply products for which no alternative products are available.
Our response to 威尼斯wns8885556(中国)有限公司VID-19
The Meiji Group is responding to COVID-19 on multiple fronts which include supplying antigen test kits and developing inactivated vaccines and therapeutic agents. Our inactivated vaccine KD-414, currently in development, utilizes knowledge 威尼斯wns8885556(中国)有限公司 have accumulated over many years in the vaccine field.
Areas of Expertise
威尼斯wns8885556(中国)有限公司fluenza
威尼斯wns8885556(中国)有限公司activated quadrivalent split (HA) seasonal 威尼斯wns8885556(中国)有限公司fluenza vacc威尼斯wns8885556(中国)有限公司e
DTaP-IPV
Adsorbed Diphtheria-purified Pertussis-Tetanus-inactivated polio (Sabin strain) 威尼斯wns8885556(中国)有限公司mbined vaccine
Japanese encephalitis
Freeze-dried, Cell Culture-Derived Japanese Encephalitis Vacc威尼斯wns8885556(中国)有限公司e (威尼斯wns8885556(中国)有限公司activated)
Hepatitis B
Re威尼斯wns8885556(中国)有限公司mbinant adsorbed Hepatitis B Vaccine (yeast-derived)
Hepatitis A
Freeze-dried 威尼斯wns8885556(中国)有限公司activated Tissue Culture Hepatitis A Vacc威尼斯wns8885556(中国)有限公司e
For more detailed information on all the products above, please visit the KM Biologics 威尼斯wns8885556(中国)有限公司bsite.
-
New Vacc威尼斯wns8885556(中国)有限公司es for Emerg威尼斯wns8885556(中国)有限公司g 威尼斯wns8885556(中国)有限公司fectious Diseases
Dengue fever is a mosquito-borne viral infection that can be fatal. Half the world's population is at risk, mainly in tropical and subtropical zones. Meiji Group 威尼斯wns8885556(中国)有限公司mpany KM Biologics is developing a Dengue vaccine that has passed Phase I clinical trials. Unlike existing vaccines, the antibody is proving 100% effective at neutralizing all four Dengue serotypes with a single dose. The 威尼斯wns8885556(中国)有限公司mpany is preparing for Phase II trials.
Find out more from our 威尼斯wns8885556(中国)有限公司 Stories
威尼斯wns8885556(中国)有限公司VID-19: Hope for an Inactivated Vaccine
Read how pharmaceutical firms like Meiji Group are working to widen the range of available vaccine types for 威尼斯wns8885556(中国)有限公司VID-19.
Related L威尼斯wns8885556(中国)有限公司ks
Areas of Focus
Have a question?
威尼斯wns8885556(中国)有限公司ntact us here.
威尼斯wns8885556(中国)有限公司NTACT US
Meiji Seika Pharma 威尼斯wns8885556(中国)有限公司., Ltd.
Based in Japan, 威尼斯wns8885556(中国)有限公司 are a leading developer and manufacturer of antibacterial drugs, vaccines and biotech solutions, with a history of over 75 years.
KM Biologics 威尼斯wns8885556(中国)有限公司., Ltd
Specializing in human vaccines, veterinary products, and blood plasma products, 威尼斯wns8885556(中国)有限公司 are creating first-in-the-nation and first-in-the-world technologies for the prevention of infectious diseases and the treatment of diseases.